Ocumetics forms scientific advisory committee to steer late-stage development of accommodating intraocular lens

Ocumetics Technology Corp ( (TSE:OTC) ) just unveiled an announcement.

Ocumetics Technology Corp., a developer of next-generation ophthalmic devices, is advancing a novel intraocular lens designed to sit in the eye’s natural lens compartment and use the eye’s own muscle activity to provide clear vision from near to far. The company is currently in a first-in-human early feasibility study phase as it works to clinically validate this accommodating lens technology for patients who might otherwise rely on glasses or contact lenses.

The company has established a Scientific Advisory Committee to guide its clinical, regulatory and commercialization strategy as it moves toward late-stage development. The committee, which includes renowned ophthalmologist and clinical researcher Dr. Ron Krueger, will advise on trial design, pivotal study execution, FDA engagement, surgical adoption and commercialization readiness, supporting Ocumetics’ push toward pivotal studies and broader market entry.

The most recent analyst rating on (TSE:OTC) stock is a Hold with a C$0.53 price target. To see the full list of analyst forecasts on Ocumetics Technology Corp stock, see the TSE:OTC Stock Forecast page.

Spark’s Take on TSE:OTC Stock

According to Spark, TipRanks’ AI Analyst, TSE:OTC is a Neutral.

The score is primarily held down by very weak financial performance (no revenue, ongoing losses, negative equity, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD, despite oversold readings. Positive corporate updates around clinical progress and financing provide some support but are not yet reflected in operating fundamentals.

To see Spark’s full report on TSE:OTC stock, click here.

More about Ocumetics Technology Corp

Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions for the ophthalmology market. The company is developing state-of-the-art accommodating intraocular lenses and other vision-enhancing technologies that aim to eliminate the need for corrective eyewear and provide clear vision at all distances.

Average Trading Volume: 36,101

Technical Sentiment Signal: Hold

Current Market Cap: C$22.6M

See more data about OTC stock on TipRanks’ Stock Analysis page.